Sanofi signs radioligand therapy licensing deal for rare cancers

Sanofi has signed a licensing agreement with RadioMedix and Orano Med to advance a radioligand therapy, AlphaMedix.

Sep 14, 2024 - 04:00

Sanofi signs radioligand therapy licensing deal for rare cancers

Sanofi has signed a licensing agreement with RadioMedix and Orano Med to advance a radioligand therapy, AlphaMedix.

Read the original article

Tags:

Previous Article

Into the unknown: How quickly can vaccines be developed for Disease X

Eli Lilly to invest $1.8bn in manufacturing capacity in Ireland

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

HUC-3443 by Huons for Idiopathic (Essential) Hypertensi...

Nov 4, 2023

STAT+: Lawmakers eye partial increase for Medicare doctor pay

STAT+: Lawmakers eye partial increase for Medicare doct...

Feb 13, 2024

Bayer wins FDA breakthrough therapy designation for NSCLC candidate

Bayer wins FDA breakthrough therapy designation for NSC...

Feb 26, 2024